{"entity":{"id":"nct07231211","kind":"trial","name":"A Study of SHR-4610 Injection in Patients With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of Trastuzumab rezetecan in advanced solid tumours, run by Shanghai Shengdi Pharmaceutical Co., Ltd, now recruiting.","summary":"A Study of SHR-4610 Injection in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07231211 by Shanghai Shengdi Pharmaceutical Co., Ltd, with 258 participants planned, started 2025-11-20 and due to reach its primary completion in 2026-10. Interventions recorded: SHR-4610 Injection and SHR-A1811 for injection.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07231211","url":"https://clinicaltrials.gov/study/NCT07231211"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["trastuzumab-rezetecan"],"companies":["hengrui"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07231211","phase":"1/2","setting":"An Open-label, Multicenter Phase I/II Clinical Study of SHR-4610 Injection in Patients With Advanced Solid Tumors to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy","sponsor":"Shanghai Shengdi Pharmaceutical Co., Ltd","enrolled":258,"outcomes":[]},"route":"/trials/nct07231211/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"trastuzumab-rezetecan","kind":"drug","name":"Trastuzumab rezetecan","route":"/drugs/trastuzumab-rezetecan/"}],"company":[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"}]}}